Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Impaired consciousness and hemiparesis following CVC removal: a rare complication].

Innere Medizin (Heidelberg, Germany)·2025
Same author

Diagnostic delay in inflammatory bowel diseases in a German population.

World journal of gastroenterology·2024
Same author

Validation of the German Inflammatory Bowel Disease Fatigue (IBD-F) Questionnaire.

Zeitschrift fur Gastroenterologie·2022
Same author

[Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease].

Zeitschrift fur Gastroenterologie·2021
Same author

A Promoter Variant Within the Aryl Hydrocarbon Receptor Gene Is Associated with an Epithelial Barrier Defect in Smokers with Crohn's Disease.

Inflammatory bowel diseases·2016
Same author

Inflammation-driven malnutrition: a new screening tool predicts outcome in Crohn's disease.

The British journal of nutrition·2016

Related Experiment Video

Updated: Jul 20, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Conventional therapy for Crohn's disease.

Carsten Büning1, Herbert Lochs

  • 1Department of Gastroenterology, Hepatology & Endocrinology, Charité Campus Mitte, Universitätsmedizin Berlin, Schumannstrasse 20/21, Berlin 10117, Germany. carsten.buening@charite.de

World Journal of Gastroenterology
|August 29, 2006
PubMed
Summary

Current Crohn

Area of Science:

  • Gastroenterology and Hepatology
  • Immunology
  • Pharmacology

Background:

  • Crohn's disease (CD) is a complex, multifactorial gastrointestinal disorder with an incompletely understood etiology.
  • Despite advances in understanding CD pathophysiology, many therapeutic agents have faced regulatory hurdles due to efficacy or safety concerns.
  • Established treatments like 5-ASA, corticosteroids, and azathioprine remain foundational for managing CD.

Purpose of the Study:

  • To provide clinicians with practical, evidence-based guidelines for the conventional management of Crohn's disease.
  • To synthesize findings from randomized controlled trials and meta-analyses to inform treatment algorithms.
  • To address clinical management gaps where controlled trial data is limited, incorporating expert opinion.

Main Methods:

Related Experiment Videos

Last Updated: Jul 20, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

  • Systematic review and synthesis of evidence from randomized, placebo-controlled trials in Crohn's disease.
  • Prioritization of meta-analyses where available to establish the highest level of evidence.
  • Development of evidence-based treatment algorithms, supplemented by expert consensus for data-deficient scenarios.

Main Results:

  • Conventional therapies, including 5-ASA, corticosteroids, and azathioprine, continue to be the primary treatment modalities for Crohn's disease.
  • Biological agents, exemplified by infliximab, demonstrate significant efficacy in challenging CD presentations, such as fistulizing or steroid-dependent disease.
  • Evidence-based algorithms are presented, acknowledging limitations and incorporating expert opinion for comprehensive clinical guidance.

Conclusions:

  • This review offers a practical framework for clinicians managing Crohn's disease, emphasizing evidence-based approaches.
  • The integration of conventional and biologic therapies is crucial for optimizing patient outcomes in Crohn's disease.
  • The guidelines aim to serve as a valuable resource in the complex therapeutic landscape of Crohn's disease.